Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Friday, May 8th. The shares were sold at an average price of $564.95, for a total transaction of $5,367,025.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,887,819.35. The trade was a 19.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

United Therapeutics Stock Up 0.8%

NASDAQ:UTHR traded up $4.63 during trading hours on Monday, hitting $569.57. 439,733 shares of the company traded hands, compared to its average volume of 486,117. The firm’s 50-day simple moving average is $550.17 and its 200-day simple moving average is $501.37. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The company has a market cap of $24.18 billion, a PE ratio of 21.03, a PEG ratio of 1.80 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same quarter last year, the business posted $6.63 earnings per share. United Therapeutics’s revenue was down 1.6% on a year-over-year basis. As a group, equities research analysts expect that United Therapeutics Corporation will post 27.4 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

Hedge funds have recently made changes to their positions in the business. AE Wealth Management LLC raised its stake in shares of United Therapeutics by 396.3% during the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after purchasing an additional 3,424 shares during the period. Great Lakes Advisors LLC raised its stake in United Therapeutics by 194.7% in the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after acquiring an additional 2,975 shares during the period. Optimize Financial Inc bought a new stake in United Therapeutics in the 3rd quarter valued at about $444,000. Tobam raised its stake in United Therapeutics by 183.9% in the 3rd quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock valued at $3,205,000 after acquiring an additional 4,953 shares during the period. Finally, Perpetual Ltd bought a new stake in United Therapeutics in the 4th quarter valued at about $1,059,000. 94.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on UTHR. Bank of America raised their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. UBS Group raised their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. HC Wainwright raised their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Raymond James Financial began coverage on United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective on the stock. Finally, Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.